Search

Displaying results 1251 - 1260 of 7687 in total
  1. Drug

    Dipotassium phosphate

    go.drugbank.com/drugs/DB09414
    ApprovedInvestigational

    Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

    Synonyms: Di-potassium hydrogen phosphateMixtures: INYECCION DE FOSFATO DE POTASIO, INYECCION DE FOSFATO DE POTASIO
  2. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

  3. Drug

    Gallium citrate Ga-67

    go.drugbank.com/drugs/DB06784
    Approved

    Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metasta...

  4. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    [T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired the denomination of orphan product by the FDA.

  5. Drug

    Bromothalonil

    go.drugbank.com/drugs/DB14199
    Approved

    It is also a known allergen and dermatological irritant that has been banned in many EU countries due to increasing rates of contact allergy [A34322]. … Bromothalonil, also known as Methyldibromo glutaronitrile (MDBGN), is a widely used preservative that can be found in many personal hygiene and industrial products.

  6. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141] … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

  7. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.

  8. Drug

    Levorphanol

    go.drugbank.com/drugs/DB00854
    Approved

    A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.

  9. Drug

    Physostigmine

    go.drugbank.com/drugs/DB00981
    Approved

    It can be applied topically to the conjunctiva. … It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.

  10. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    It is not currently FDA-approved. … Due to its long duration of action, lacidipine does not lead to reflex tachycardia [A31536].